Marea Therapeutics Secures $190M to Lead Genetic Breakthroughs in Cardiometabolic Medicine

South San Francisco, CA, June 18, 2024 (Business Wire) -- Marea Therapeutics, raises $190 million from leading investors, to pioneer advancements in cardiometabolic medicine. The funding supports Phase 2 trials for its lead program, MAR001, a monoclonal antibody targeting a key protein in fat metabolism. Incubated by Third Rock Ventures, Marea is poised to innovate in the genetic treatment of cardiometabolic diseases.

Read full article here.